Navigation Links
Adherence course reduces hypertension
Date:2/16/2011

A high proportion of patients with high blood pressure are failing to take their medication properly and would benefit clinically from a course of 'adherence therapy', according to new research from the University of East Anglia (UEA).

High blood pressure or hypertension is one of the major cardiovascular diseases worldwide. It leads to stroke and heart disease and costs more than $300 billion each year. Around a quarter of the adult population is affected including 10 million people in the UK.

Around half of patients with hypertension fail to reduce their blood pressure because they are not taking their prescribed medication correctly. Some cease taking their medication altogether, others only take some of it, and others do not follow the instructions to take their medicine after food, for example.

The reasons for this non-adherence are complex and include ambivalence about taking drugs, concerns over side effects, and complexity of treatement regimes. Previous attempts to improve adherence with information leaflets, monthly outpatient visits, reminders and self-monitoring have been shown to be mostly ineffective.

The UEA resesarchers studied 136 patients with high blood pressure in three outpatient clinics in Jordan. Half were given a course of seven weekly 'adherence therapy' sessions and half continued with their usual treatment. The 20-minute face-to-face sessions allowed a trained clinician to provide tailored information about the illness and treatment, and explore the patient's individual beliefs, fears and lifestyle.

Published today in the Journal of Human Hypertension, the results show that the patients given adherence therapy took 97 per cent of their medications (compared with only 71 per cent for those given treatment as usual) and, on average, reduced their blood pressure by around 14 per cent taking it to just above the healthy range.

Lead author Prof Richard Gray of UEA's School of Nursing and Midwifery said: "Our findings suggest a clear clinical benefit in these patient-centred sessions.

"High blood pressure affects millions of people in both the developed and developing world and the problem is likely to increase dramatically over the next 15 years. Tackling the widespread failure to take medication correctly would lead to a major reduction in stroke and heart disease.

"If adherence therapy were a new drug it would be hailed as a potentially major advance in hypertension treatment."

Adherence therapy was originally developed by Prof Gray for patients with mental health problems who failed to take their medication correctly. The total cost of delivering a course of seven weekly sessions is calucated to be approximately 80 per person. Although the UEA study was not designed to formally evaulate cost effectiveness, other studies predict that a long-term reduction of blood pressure would lead to a reduction in stroke of 56 per cent and a reduction in chronic heart disease of 37 per cent suggesting that adherence therapy would likely be a cost-effective intervention.


'/>"/>

Contact: Simon Dunford
s.dunford@uea.ac.uk
44-160-359-2203
University of East Anglia
Source:Eurekalert

Related medicine news :

1. Side effects of hormonal breast cancer therapy increased; may affect treatment adherence
2. Medication adherence improves blood pressure control in chronic kidney disease
3. Adherence to practice guidelines may reduce bleeding in cirrhosis patients
4. Electronic Monitoring of Asthma Med Use May Boost Adherence
5. NACDS RxIMPACT "Hill Day" Features More Advocates Increased Focus on Medication Adherence
6. Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines
7. NHGRI charts course for the next phase of genomics research
8. CTO summit and left main coronary interventions course will feature latest research and techniques
9. CTO Summit & Left Main Coronary Interventions Course to be held Feb. 14-16, 2011, in NYC
10. Strong scientific findings presented at AIDS 2010 point to promise ahead and underscore the need to stay the course
11. Atlanta School of Sleep Medicine Offers Physician Board Review Course in October 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... 2017 , ... A yellow fever outbreak in Brazil has infected over 100 ... primarily spread through contact with infected mosquitos. The outbreak has sparked increased concern about ... , According to multiple health organizations, the best way to prevent yellow fever is ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing Wisdom-Solomon’s Proverbs ... friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. , “Choosing ... Coats and Dr. David Coats. In September of 1983, they flew to Haiti ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Mysteries Revealed On Speaking In Tongues”: ... phenomenon is available to all Christians. “Mysteries Revealed On Speaking In Tongues” is the ... Creation,” a Christian-based talk show located in Michigan. , “We need to partner ...
(Date:1/24/2017)... ... January 24, 2017 , ... Attention women who want ... suggests that autologous fat grafting—taking one’s own fat and putting it in other ... , Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology Surgery & ...
(Date:1/24/2017)... IL (PRWEB) , ... January 23, 2017 , ... ... is partnering with Plug and Play, the world’s largest start-up platform headquartered in ... companies a year. , OSF Ventures recently signed a three-year agreement to ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017 The Pharmacy ... the implementation of the planned 2020 accredited education ... PTCB originally announced in 2013 that the requirement ... a road map of program changes designed to ... in the pharmacy. "We have ...
(Date:1/23/2017)... 2017  Therabron Therapeutics, Inc., a clinical-stage biotechnology ... respiratory care, today announced that the European Medicines ... granted Orphan Drug Designation for Therabron,s CG367 program, ... (BOS).  "We are pleased to have ... treat patients diagnosed with BOS following lung transplantation. ...
(Date:1/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The interventional radiology products market is expected to reach ... at a CAGR of 4.8%. This market is segmented based on ... the growth of this market are rising incidence of chronic diseases, ...
Breaking Medicine Technology: